AVT-VAL-104-P · copy 003PDF
Source excerpt · Page 1; issued-and-executed copy 003
Havenor Therapeutics · Its newest medicine, Avericin, is finished and waiting for a health authority to approve it.
Task 03 · Principal MSAT Engineer
Review the AVI-401 sterile-filter validation studies
Review whether the filter-validation package would hold up in front of the regulator.
Claude Opus 5 caught 5 of 9 traps. See which →
3What just happened?
Havenor is about to discuss its sterile-filter tests with the regulator.
Avericin is sterilized by pushing it through a filter fine enough to hold back bacteria. A package of four validation studies proves the filter works. Before the meeting, someone must check it would survive a reviewer’s questions.
4Who has to do what?
Review whether the filter-validation package would hold up in front of the regulator.
- The seat
- Marcus Fernandes, Principal MSAT Engineer
- What a good answer looks like
- It accepts that the results pass and focuses on the paperwork behind them: gaps in scale-up, missing links between tests, rules that aren’t in the plan, and the limits the results actually cover.
- What must be handed in
AVI401_filter_validation_defensibility_review.docx
The assignment as the model received it
Review the approved and executed evidence, then write an inspector-facing defensibility assessment without changing controlled records.
5Which files decide it?
Four filter-validation reports, their approved test plans, and the observations and deviations recorded during testing.
The model also has the rest of the company’s shared drive, its chat and its record systems. Finding the right files is part of the job. Flip through the key ones below.
Company documents
Some of the documents available to the model.
Executed protocol · scanned PDF
What was actually done?
The validation package includes plans, a scanned executed copy, and a report. The reviewer has to reconcile all three.
The model must check whether the work recorded in the protocol supports the report’s conclusions.
6What did the model do?
What Claude Opus 5 did, step by step.
In short: Opus reads the validation reports and views the scanned executed protocols page by page before writing an inspector-facing review.
Step 9. Reads the retention report. The approved bacterial-retention report assesses its observation against a 30-minute inoculation window and says the protocol defines it.
Report text read by the modelthe protocol-defined 30-minute window
Step 21. Opens the executed-protocol scans. Opus renders the scanned executed copy of the retention protocol and views the page images directly, because the scan has no text layer.
Image opened by the model/tmp/e107-14.png
Step 51. Repeats the report’s window. The review repeats the 30-minute window as protocol-defined. It never checks the approved protocol, which contains no such window, so the grader marks the finding as missed.
Text written into the reviewassessed against the protocol-defined 30-minute window
Replay every step of the run →
Inside the run
A
Model
Reads the retention report
Tool result
the protocol-defined 30-minute window
A
The approved bacterial-retention report assesses its observation against a 30-minute inoculation window and says the protocol defines it.
1 / 3
7Which traps did it catch?
It caught 5 of 9.
Specialists wrote these checks from the real records before any model ran. Each is a weak spot a reviewer or inspector would find. A check passes only if the handed-in file states it.
Missed
Only one of two integrity tests is linked to bacteria R03
The package links the “bubble point” check to bacteria removal, but not the second integrity check (“diffusive flow”) that the specification also uses.
If missed, a routine check is trusted without proof that it detects a bad filter.
A 30-minute window that isn’t in the plan R04
A note explaining a problem in the bacteria test relies on a 30-minute time window that the approved test plan never mentions.
If missed, the excuse for a test problem rests on a rule that was never agreed.
State the tested limits R07
The results cover at most 8 hours of contact, 30 °C and a 2.1 bar pressure drop, and nothing beyond.
If missed, the filter could be run outside the conditions it was tested for.
“Accepted” is not “closed” R08
One issue in the bacteria study was accepted as-is; two other issues were investigated and closed. They are different outcomes.
If missed, an accepted risk is presented as a resolved one.
Caught
The results pass; the paperwork is the question R01
All four studies meet their approved criteria. What’s in doubt is the evidence of how they were run.
If missed, the review attacks passing results instead of the real gaps.
The small test filter isn’t linked to the real one R02
Tests used a small 47 mm disc (13.8 cm²). No area, flow or throughput is recorded for the full-size production cartridge.
If missed, nobody can show the lab test represents the factory filter.
Approved before the evidence existed R05
One acceptance rule depends on the bacteria-removal report, yet it was signed before that report existed.
If missed, a conclusion is accepted that couldn’t have been supported when it was signed.
The bacteria challenge did pass R06
The filters held back far more bacteria than the minimum (about 1.2–1.4 × 10⁸ per cm² against 10⁷), with none getting through.
If missed, the review undersells results that are genuinely strong.
No scale-up factor can be computed R09
Because the production cartridge’s filter area appears nowhere in the records, no ratio between test and production filter can be worked out from them.
If missed, a number gets invented from outside the record.
Every model on the same job
One attempt each, same assignment and checklist, so treat small gaps as noise.
Submitted document
AVI401_filter_validation_defensibility_review.docx
1 / 11
Talk to usRequest the full Biopharma Bench V0.1 — company environments and run receipts: team@raycaster.ai